Clinically, these findings were confirmed in patients with advanced melanoma treated with domatinostat for 14 days who displayed elevated expression of APM and MHC genes, and the IFN-γ and pembrolizumab response signatures in individual tumor samples. This evidence concerns the gene HLA-C and neoplasm.